Polaryx Therapeutics (PLYX) CFO Landis G. Michael buys 2,867 shares

Rhea-AI Filing Summary

Polaryx Therapeutics, Inc. director and Chief Financial Officer Landis G. Michael reported an open-market purchase of common stock. On February 18, 2026, he bought 2,867 shares at an average price of $2.7871 per share, bringing his directly held stake to 228,225 shares.

Insider Trade Summary

Net Buyer: 2,867 shares ($7,991)

Net Buy 1 txn

Insider Landis G. Michael

Role Chief Financial Officer

Bought 2,867 shs ($8K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,867	$2.7871	$8K

Holdings After Transaction: Common Stock — 228,225 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landis G. Michael

(Last) (First) (Middle)

SOUTH TOWER, 140 E RIDGEWOOD

AVENUE, SUITE 415

(Street)

PARAMUS NJ 07652

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Polaryx Therapeutics, Inc. [ PLYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		P		2,867	A	$2.7871	228,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ G. Michael Landis	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PLYX director and CFO Landis G. Michael report?

Landis G. Michael reported buying 2,867 shares of Polaryx Therapeutics common stock. The transaction was an open-market purchase, indicating he directly increased his personal shareholdings in the company’s common stock.

At what price did Landis G. Michael buy Polaryx Therapeutics (PLYX) shares?

He purchased the shares at an average price of $2.7871 per share. This price reflects what he paid in the open market on the transaction date for the 2,867 common shares acquired.

How many Polaryx Therapeutics (PLYX) shares does Landis G. Michael own after this transaction?

Following the reported purchase, Landis G. Michael directly owns 228,225 shares of Polaryx Therapeutics common stock. This total includes the newly acquired 2,867 shares bought in the open-market transaction.

When did the recent insider share purchase for Polaryx Therapeutics (PLYX) occur?

The reported insider purchase took place on February 18, 2026. On that date, Landis G. Michael acquired 2,867 shares of Polaryx Therapeutics common stock in an open-market transaction.

Was the Polaryx Therapeutics (PLYX) insider transaction a buy or a sell?

The transaction was a buy. Landis G. Michael executed an open-market purchase of 2,867 shares of Polaryx Therapeutics common stock, increasing his direct ownership position in the company.

What type of security did Landis G. Michael trade in the Polaryx Therapeutics (PLYX) Form 4?

He traded Polaryx Therapeutics common stock. The Form 4 shows a non-derivative transaction where he directly bought 2,867 common shares in an open-market purchase at $2.7871 per share.